COVID-19 Testing: More details
COVID-19 Resources: More details
ImmuniMed Inc. is an innovative, clinical-stage, Research & Development Biopharmaceutical Company. ImmuniMed Inc. develops oral antibody therapy using passive vaccination to treat and prevent gastro-enteric infections. Their technology is designed to utilize chicken eggs as bioreactors to manufacture specific polyclonal antibodies – a new class of biopharmaceuticals.
member
The $4.95 million, to be doled out over the next six years, will support programs at the U of M, the University of Guelph and McGill University, as well as seven additional institutions.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.